Osteosarcoma is a disease in which the recent lack of progress in improving patient survival strongly suggests the need for novel treatment approaches. Dr. Gorlick's Pediatric Preclinical Testing Consortium laboratory within the Albert Einstein College of Medicine has more than 15 years of experience evaluating novel anti-cancer agents in a panel of well-characterized osteosarcoma patient-derived xenografts. Drug response and genomic profiling of the osteosarcoma panel are consistent with clinical specimens. The laboratory is focused on identifying novel therapies with activity in osteosarcoma, understanding the mechanisms of resistance to targeted therapies, and prioritizing novel agents for clinical development.
Children's Hospital at Montefiore